We're starting to see some data on how well a two-dose vaccine series protects people from the omicron variant. It seems scary, but it actually might be hopeful? Meanwhile, Canada has been slow to scale up its booster shot program. Will the new variant give governments some urgency to move faster? And what about kids who just had their first dose or younger ones who haven't had any? How do they fare against the new variant?
GUEST: Sabina Vohra-Miller, clinical pharmacologist